5 December 2019 - PHARMAC is pleased to announce a decision to widen access to bortezomib for patients with multiple myeloma and amyloid light-chain amyloidosis in conjunction with a change of funded brand of bortezomib through PHARMAC’s annual tender process.

In summary:

• From 1 March 2020 the Dr Reddy's brand of bortezomib will be funded and access to bortezomib will be widened so it can be used at any time in the treatment of multiple myeloma and AL amyloidosis and the number of treatment cycles will no longer be limited
• From 1 August 2020 the Velcade brand of bortezomib will be delisted and the Dr Reddy’s brand of bortezomib will be the only funded brand from 1 August 2020 until 30 June 2022.

Read PHARMAC Notification